Quarterly Result14 May 2026, 02:32 pm
Senores Pharma FY26 Revenue Up 65% to ₹664 Cr
AI Summary
Senores Pharmaceuticals Ltd announced its audited consolidated and standalone financial results for FY26. The company reported a 65% increase in total income to ₹664 Cr and a 114% increase in EBITDA to ₹200 Cr. PAT increased by 108% to ₹122 Cr. The company highlighted strong growth in regulated markets, emerging markets, and branded generics businesses, along with strategic acquisitions and a joint venture in the U.S. Federal Market.
Key Highlights
- FY26 total income reached ₹664 Cr, a 65% increase year-over-year.
- EBITDA for FY26 stood at ₹200 Cr, up 114% year-over-year.
- Branded Generics revenue grew by approximately 385% year-over-year for FY26.
- Acquired a 51% stake in Zoraya Pharmaceuticals and a 75% stake in Apnar Pharmaceuticals.
- Entered the U.S. Federal Market via a 70% joint venture, Amerisyn.